Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2684| Título : | Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age |
| Creador: | Sáez Llorens, Xavier |
| Nivel de acceso: | Open access |
| Palabras clave : | Antifúngicos - administración & dosificación Antifúngicos -efectos adversos Antifúngicos -sangre Antifúngicos - farmacocinética Body Surface Area Candidiasis - quimioterapia Ensayo Clínico Esquema de Medicación Equinocandinas - administración & dosificación Equinocandinas - efectos adversos Equinocandinas - sangre Equinocandinas - farmacocinética fiebre - inducido químicamente Hipertensión - inducido químicamente Hiperventilación - inducido químicamente Lactante Recién nacido Infusiones Intravenosas Antifungal Agents - administration & dosage Antifungal Agents - adverse effects Antifungal Agents - blood Antifungal Agents - pharmacokinetics Body Surface Area Candidiasis - drug therapy Clinical Trials Drug Administration Schedule Echinocandins - administration & dosage Echinocandins - adverse effects Echinocandins - blood Echinocandins - pharmacokinetics Fever - chemically induced Hypertension - chemically induced Hyperventilation - chemically induced Infant Infant, Newborn Infusions, Intravenous |
| Descripción : | Candida infections represent a major threat in neonatal intensive care units. This is the first prospective study to obtain caspofungin plasma levels and safety data for neonates and very young infants. Patients of <3 months of age receiving intravenous amphotericin B for documented or highly suspected candidiasis were enrolled in a single-dose (n = 6) or subsequent multiple-dose (n = 12) panel; all received caspofungin at 25 mg/m 2 once daily as a 1-hour infusion. Caspofungin plasma levels were measured by high-performance liquid chromatography and compared to historical data from adults. Patient chronological ages ranged from 1 to 11 weeks, and weights ranged from 0.68 to 3.8 kg. Gestational ages ranged from 24 to 41 weeks. Geometric mean (GM) peak (C 1 h) and trough (C 24 h) caspofungin levels were 8.2 and 1.8 μg/ml, respectively, on day 1, and 11.1 and 2.4 μ/ml, respectively, on day 4. GM ratios for C 1 h and C 24 h for neonates/infants relative to adults receiving caspofungin at 50 mg/day were 1.07 and 1.36, respectively, on day 1, and 1.18 and 1.21, respectively, on day 4. Clinical and laboratory adverse events occurred in 17 (94%) and 8 (44%) patients, respectively. Five patients (28%) had serious adverse events, none of which were considered drug related. Caspofungin at 25 mg/m 2 once daily was well tolerated in this group of neonates/infants of <3 months of age and appears to provide relatively similar plasma exposure to that obtained in adults receiving 50 mg/day. However, the small number of patients studied precludes any definitive recommendations about caspofungin dosing for this group comprising a broad range of ages and weights. Copyright © 2009, American Society for Microbiology. All Rights Reserved. |
| Colaborador(es) u otros Autores: | Macias M Maiya P Pineros J Jafri HS Chatterjee A Ruiz G Raghavan J Bradshaw SK Kartsonis NA Sun P Strohmaier KM Fallon M Bi S Stone JA Chow JW |
| Fecha de publicación : | 2009 |
| Tipo de publicación: | Artículo |
| Formato: | |
| Identificador del Recurso : | 10.1128/AAC.00868-08 |
| Fuente: | Antimicrobial Agents and Chemotherapy 53(3):869 - 875 |
| URI : | http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2684 |
| Idioma: | eng |
| Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.